Approval · Notice of Compliance 16285 · 2014
VAN-GABAPENTIN: Notice of Compliance 16285
Issued November 14, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16285
- Date
- November 14, 2014
- Company
- Vanc Pharmaceuticals IncRichmond, British Columbia, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- Antiepileptic agent
- Canadian reference product
- NEURONTIN (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VAN-GABAPENTIN | 02432544 | Cancelled Post Market |
| VAN-GABAPENTIN | 02432552 | Cancelled Post Market |
Medicinal ingredients
- GABAPENTIN 600 MG per TAB
- GABAPENTIN 800 MG per TAB